Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Royal Philips    PHIA   NL0000009538

ROYAL PHILIPS

(PHIA)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Royal Philips : Philips sales spurred by rising Chinese healthcare spending

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/22/2019 | 04:53am EDT
FILE PHOTO:  Dutch health technology company Philips presents the company's financial results for the fourth quarter in Amsterdam

AMSTERDAM (Reuters) - Rising healthcare spending by the Chinese government helped Dutch health technology company Philips post better-than-expected sales growth for the second quarter, putting its shares among the top performers in Europe on Monday.

Philips, which sells products ranging from toothbrushes to medical imaging systems, said comparable sales had improved 6% in the second quarter. Analysts had on average only penciled in a 4.5% improvement.

Philips shares rose 4% in the first hours of trading in Amsterdam, making them one of the top performers in the Stoxx600.

Growth was helped by a "double digit" sales increase in China, Philips said, as the Chinese government ramps up healthcare spending, expanding hospitals and investing in more advanced technologies.

"Healthcare in China is still not sufficient to meet the demands of an ageing society," Chief Executive Frans van Houten told Reuters in a phone interview.

"The government has said it would expand capacity, and that is exactly what is happening. This trend for us is more important than fluctuations in GDP (gross domestic product) growth, and we expect it to continue in the coming years."

Demand and orders for hospital equipment, medical systems and personal care devices also increased in the United States and Europe, keeping Philips optimistic about the months to come.

"We saw growth in all our segments in the second quarter and we expect that to continue", Van Houten told reporters.

"We had strong traction in emerging markets and that is set to continue. Also, we expect mature markets to come in stronger in the second half of the year."

TARIFF CLOUDS

Although sales in the U.S. and China remained strong, Philips said the trade disputes between the two countries remained its main worry, as both its end products and components are hit by new tariffs.

"The main cloud hanging over us is the possible fourth batch of tariffs," Van Houten said. "If that would happen, it would increase the amount by which our earnings are hit by 20 million euros this year, but nobody knows whether it will happen."

Philips currently expects tariffs to shave 45 million euros ($51 million) off its 2019 core earnings.

Once a sprawling conglomerate, Philips is now purely focused on healthcare after spinning off its lighting and consumer electronics divisions in recent years.

The company reaffirmed its target for total comparable sales growth of 4% to 6% per year until 2020, and said its profit margin would move up from 13.1 to around 14% this year.

Adjusted earnings before interest, taxes and amortization (EBITA) jumped 14% to 549 million euros in the second quarter, while the margin climbed 60 basis points to 11.8%, roughly meeting expectations.

(Reporting by Bart Meijer; Editing by Sherry Jacob-Phillips and Edmund Blair)

By Bart H. Meijer

Stocks mentioned in the article
ChangeLast1st jan.
ROYAL PHILIPS 1.71% 41.65 Delayed Quote.34.66%
STOXX EUROPE 600 1.24% 369.63 Delayed Quote.9.47%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROYAL PHILIPS
08/16ROYAL PHILIPS : How tomorrow's cancer care will be tailored to each patient
PU
08/16ROYAL PHILIPS : Philips' Simona Comandè ranked among top 100 most successful Ita..
PU
08/16Periodic update on transaction details related to Philips' share repurchases
GL
08/12ROYAL PHILIPS : Philips' response to updated FDA letter to healthcare providers ..
PU
08/12ROYAL PHILIPS : How Can Technology Better Support Acute Patient Care?
PU
08/09Periodic update on transaction details related to Philips' share repurchases
GL
08/08Germany's Siemens Healthineers to buy U.S. firm Corindus for $1.1 billion
RE
08/05ROYAL PHILIPS : Why it's time for a paradigm shift in lung cancer treatment
PU
08/05ROYAL PHILIPS : Periodic update on transaction details related to Philips' share..
AQ
08/02ROYAL PHILIPS : New study from Philips reveals the importance of partner partici..
AQ
More news
Financials (EUR)
Sales 2019 19 377 M
EBIT 2019 2 538 M
Net income 2019 1 479 M
Debt 2019 3 299 M
Yield 2019 2,09%
P/E ratio 2019 26,4x
P/E ratio 2020 21,6x
EV / Sales2019 2,11x
EV / Sales2020 1,98x
Capitalization 37 508 M
Chart ROYAL PHILIPS
Duration : Period :
Royal Philips Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROYAL PHILIPS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 43,44  €
Last Close Price 41,65  €
Spread / Highest target 24,8%
Spread / Average Target 4,29%
Spread / Lowest Target -16,0%
EPS Revisions
Managers
NameTitle
Frans van Houten Chief Executive Officer
Jeroen van der Veer Chairman-Supervisory Board
Sophie Bechu Chief Operating Officer & Executive Vice President
Abhijit Bhattacharya Chief Financial Officer & Executive Vice President
Jan Kimpen Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ROYAL PHILIPS34.66%40 948
THERMO FISHER SCIENTIFIC22.13%109 454
DANAHER CORPORATION33.04%98 416
BOSTON SCIENTIFIC CORPORATION18.48%58 324
INTUITIVE SURGICAL3.45%57 612
EDWARDS LIFESCIENCES CORPORATION40.50%44 757